Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia.
Link to Enroll: https://herspiegelconsulting.qualtrics.com/jfe/form/SV_b2XgO2Ok1rd5W0m
Disclaimer: This research opportunity is not affiliated with NAF. We are sharing this information as a resource for the Ataxia community. Sharing this information does not imply endorsement by NAF.
About the Study
Eligible Ataxia Types
SCA2 and SCA3
Type of Study
Survey
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
06/09/2025
Estimated Completion Date
08/18/2025
IRB Approval #
N/A
Location(s)
Servier Laboratories
Remote Study
Contact Information
Please send questions about this study to the NAF Research Team.
What does participation in the study entail?
Participants will be ask to read a short slide show about SCA2 and SCA3, as well as Antisense Oligonucleotide (ASO) therapy. Then participants will be asked to fill out a short survey. The survey will take approximately 15 minutes to complete.
What are the potential benefits for participants?
Participating in this study will not directly benefit participants. However, the opinions shared by participants will be used to improve future SCA2 and SCA3 clinical trials.
What are the potential risks for participants?
This study is has minimal risks. Answering questions may cause participants to feel uncomfortable, embarrassed, anxious or upset. This survey is completely voluntary, and participants may choose to opt out of this survey at any point.
Is there financial compensation?
No.
Is there travel reimbursement?
No.
Who is eligible?
This survey is open to individuals who are at risk for, or diagnosed with SCA type 2 (SCA2) or type 3 (SCA3) who live in the United States. To be eligible, participants must still be able to walk independently without the permanent use of aids, and must have reached the age of majority in their state of residence. Family members or caregivers of such individuals with SCA2 or SCA3 are also welcome to participate on behalf of the patient.
Additional Information or Resources
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
